Hiv-1 Drug Resistance in Antiretroviral-Naive Individuals with HIV-1-Associated Tuberculous Meningitis Initiating Antiretroviral Therapy in Vietnam

Little S.J. , Holte S. , Routy J.P. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385–394.

Barbour J.D. , Hecht F.M. , Wrin T. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18: 1683–1689.

Pao D. , Andrady U. , Clarke J. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37: 1570–1573.

Wittkop L. , Günthard H.F. , de Wolf F. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363–371.

Poggensee G. , Kucherer C. , Werning J. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 2007; 8: 511–519.

Hogg R.S. , Bangsberg D.R. , Lima V.D. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3: e356.

Kozal M.J. , Hullsiek K.H. , Macarthur R.D. The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007; 8: 357–370.

UK Drug Resistance database. HIV drug resistance in the United Kingdom. Commun Dis Rep CDR Wkly 2003; 13: 10–15.

Sagir A. , Oette M. , Kaiser R. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 2007; 60: 843–848.

Vercauteren J. , Derdelinckx I. , Sasse A. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008; 24: 355–362.

Jain V. , Liegler T. , Vittinghoff E. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS ONE 2010; 5: e15510.

Sax P.E. , Islam R. , Walensky R.P. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316–1323.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 10 January 2011. Accessed 18 April 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Gazzard B.G. , Anderson J. , Babiker A. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563–608.

UNAIDS. Vietnam 2010 country progress report on following up the implementation to the declaration of commitment on HIV and AIDS. Hanoi, Vietnam: Ministry of Health 2010.

Lan N.T.H. , Recordon-Pinson P. , Hung P.V. HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res Hum Retroviruses 2003; 19: 925–928.

Nguyen H.T. , Duc N.B. , Shrivastava R. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 2008; 13 Suppl 2: 115–121.

Ishizaki A. , Cuong N.H. , Thuc P.V. Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Vietnam. AIDS Res Hum Retroviruses 2009; 25: 175–182.

Ayouba A. , Lien T.T. , Nouhin J. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses 2009; 25: 1193–1196.

Phan T.T.C. , Ishizaki A. , Phung D.C. , Bi X. , Oka S. , Ichimura H. Characterization of HIV type 1 genotypes and drug resistance mutations among drug-naive HIV type 1-infected patients in northern Vietnam. AIDS Res Hum Retroviruses 2010; 26: 233–235.

Dean J. , Ta Thi T.H. , Dunford L. Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. AIDS Res Hum Retroviruses 2011; 27: 797–801.

Bennett D.E. , Myatt M. , Bertagnolio S. , Sutherland D. , Gilks C.F. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2: 25–36.

Török M.E. , Yen N.T.B. , Chau T.T.H. Timing of initiation of antiretroviral therapy in human immunodeficiency virus associated tuberculous meningitis. Clin Infect Dis 2011; 52: 1374–1383.

Thwaites G.E. , Nguyen D.B. , Nguyen H.D. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741–1751.

Boom R. , Sol C.J. , Salimans M.M. , Jansen C.L. , Wertheim-van Dillen P.M. , van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495–503.

Loens K. , Bergs K. , Ursi D. , Goossens H. , Ieven M. Evaluation of NucliSens easyMAG for automated nucleic acid extraction from various clinical specimens. J Clin Microbiol 2007; 45: 421–425.

Bezemer D. , Jurriaans S. , Prins M. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 2004; 18: 1571–1577.

Bennett D.E. , Camacho R.J. , Otelea D. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.

Johnson V.A. , Brun-Vézinet F. , Clotet B. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156–163.

Tamura K. , Dudley J. , Nei M. , Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596–1599.

Los Alamos National Library HIV Database. (Updated April 2010. Accessed 1 September 2010.) Available from http://www.hiv.lanl.gov/content/index.

Liu J. , Yue J. , Wu S. , Yan Y. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China. Arch Virol 2007; 152: 1799–1805.

Thwaites G.E. , Duc Bang N. , Huy Dung N. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis 2005; 192: 2134–2141.

Vietnam Ministry of Health IHRD. Harm reduction developments 2008: countries with injection-driven HIV epidemics. New York: International Harm Reduction Development Program of the Open Society Institute. (Updated 1 March 2008. Accessed 31 March 2011.) Available from http://www.soros.org/initiatives/health/focus/ihrd/articles_publications/publications/developments_20080304/developments_20080304.pdf.

Weinstein M.C. , Goldie S.J. , Losina E. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134: 440–450.

Sungkanuparph S. , Oyomopito R. , Sirivichayakul S. HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis 2011; 52: 1053–1057.

Gatanaga H. , Ode H. , Hachiya A. , Hayashida T. , Sato H. , Oka S. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. Antimicrob Agents Chemother 2010; 54: 1596–1602.

Scherrer A.U. , Hasse B. , von Wyl V. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Med 2009; 10: 647–656.

Collins J.A. , Thompson M.G. , Paintsil E. , Ricketts M. , Gedzior J. , Alexander L. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004; 78: 603–611.

Eshleman S.H. , Guay L.A. , Mwatha A. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs 6–8 weeks after single-dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20: 595–599.

Schuurman R. , Demeter L. , Reichelderfer P. , Tijnagel J. , de Groot T. , Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999; 37: 2291–2296.